Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Vanguard Total International Bond Index Fund ETF (BNDX) Price & Performance

AbbVie IncTrade
Vanguard Total International Bond Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Vanguard Total International Bond Index Fund ETF — how do they compare? AbbVie Inc trades at $248.07 (market cap $441.94B), while Vanguard Total International Bond Index Fund ETF trades at $47.81. The key difference: AbbVie Inc pays a 2.77% dividend while Vanguard Total International Bond Index Fund ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.

ABBVBNDX
Market Cap
$441.94B
Sector
Health
52-Week High
$263.58$49.91
52-Week Low
$197.38$47.57
Enterprise Value
$506.19B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.

Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.

Vanguard Total International Bond Index Fund ETF

BNDX trades at $47.835 with minimal daily movement (+0.09%), showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts of $0.11-$0.12. Market sentiment reflects ongoing concerns about Treasury yields and inflation data, with institutional activity showing mixed positioning changes among major holders.

The international bond ETF faces headwinds from rising global yields and inflation pressures, though steady dividend income provides support. Key risks include Federal Reserve policy uncertainty and Middle East geopolitical tensions affecting oil prices. Institutional interest remains active with recent position adjustments, suggesting cautious but engaged professional investor sentiment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Vanguard Total International Bond Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.

Read more on BNDX